KCNA3 and prostate carcinoma: For example, Fraser et al. [44] showed for isogenic rat prostate cancer cells (i) that Kv1.3 was the dominant VGPC and (ii) that VGPC / Kv1.3 inhibitors were much more effective in suppressing the proliferation of the weakly/non-metastatic AT-2 cells compared with the strongly metastatic, VGSC-expressing Mat-LyLu cells.